BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) — Inozyme Pharma, Inc. INZY (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced that it will present three posters at the American Society for Bone and Mineral Research…Read More
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research ASBMR 2023 Annual Meeting Inozyme Pharma NASDAQINZY
